Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial | Zendy

Claudine Duvivier | Zendy; Jade Ghosn | Zendy; Lambert Assoumou | Zendy; Cathia Soulié | Zendy; Gilles Peytavin | Zendy; Vincent Cálvez | Zendy; Michèle Genin | Zendy; JeanMichel Molina | Zendy; Olivier Bouchaud | Zendy; Christine Katlama | Zendy; Dominique Costagliola | Zendy

Open Access

Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial

Author(s) -

Claudine Duvivier,

Jade Ghosn,

Lambert Assoumou,

Cathia Soulié,

Gilles Peytavin,

Vincent Cálvez,

Michèle Genin,

JeanMichel Molina,

Olivier Bouchaud,

Christine Katlama,

Dominique Costagliola

Publication year - 2008

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkn278

Subject(s) - regimen , medicine , reverse transcriptase inhibitor , nucleoside reverse transcriptase inhibitor , gastroenterology , clinical endpoint , protease inhibitor (pharmacology) , viral load , interim analysis , randomized controlled trial , stavudine , surgery , antiretroviral therapy , virology , human immunodeficiency virus (hiv)

The aim of this study was to evaluate the impact on body fat of nucleoside reverse transcriptase inhibitor (NRTI)-sparing regimens compared with NRTI-containing therapy in HIV-1-infected antiretroviral (ARV)-naive patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research